Showing 911-920 of 951 results for "".
- Phase 3 Valbenazine for Chorea in Huntington Disease Completes Enrollmenthttps://practicalneurology.com/news/phase-3-valbenazine-for-chorea-in-huntington-disease-completes-enrollment/2469660/The phase 3 KINECT-HD clinical study (NCT04102579) of valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) for treatment of chorea in Huntington disease (HD) has completed enrollmen
- Flavonoids May Reduce Risk of Subjective Cognitive Declinehttps://practicalneurology.com/news/flavonoids-may-reduce-risk-of-subjective-cognitive-decline/2469656/A study published in Neurology suggests the risk of cognitive decline may be lowered by as much as 20% with a diet rich in flavonoids. Foods that are high in flavonoids include strawberries, oranges, pepp
- Pimavanserin Effective for Dementia-Related Psychosishttps://practicalneurology.com/news/pimavanserin-effective-for-dementia-related-psychosis/2469641/As published in The New England Journal of Medicine, pimavanserin (Acadia Pharmaceuticals; San Diego, CA) treatment made relapse of dementia related psychosis (DRP) almost 3 times less likely. Results of the phase 3 H
- Phase 3 Study of Tolperisone for Muscle Spasms Reaches 50% Enrollmenthttps://practicalneurology.com/news/phase-3-study-of-tolperisone-for-muscle-spasms-reaches-50-enrollment/2469609/For the phase 3 RESUME-1 clinical study (NCT04671082) of tolperisone (Mydocalm; Neurana Pharmaceuticals, San Diego, CA), 500 of the planned 1,000 participants have enrolled. Tolperisone works as a centrally active muscle relaxant for treatment of acute and painful muscles spasms of the back.
- Rimegepant Now Approved for Both Acute and Preventive Migraine Treatmenthttps://practicalneurology.com/news/rimegepant-now-approved-for-both-acute-and-preventive-migraine-treatment/2469603/The FDA has approved rimegepant (Nurtec; Biohaven Pharmaceuticals, New Haven, CT) for the additional indication of preventive treatment of migraine. The approval for preventative migraine treatment makes rimegepant the first drug approved to treat acute migraine attacks and help prevent future mi
- FDA Approves Pimavanserin Administration by Opening Capsule and Sprinkling Onto Food or Into Liquidhttps://practicalneurology.com/news/fda-approves-pimavanserin-administration-by-opening-capsule-and-sprinkling-onto-food-or-into-liquid/2469448/The Food and Drug Administration (FDA) approved a supplement application to update the pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) prescription information. This update provides instructions for sprinkling the contents of pimavanserin capsules on food and liquids for dosing and
- Ghrelin Advances to a Phase 2 Trial for Concussion Treatmenthttps://practicalneurology.com/news/ghrelin-advances-to-a-phase-2-trial-for-concussion-treatment/2469406/A phase 2 clinical trial (NCT04558346) of ghrelin (OXE103; Oxeia Biopharmaceuticals, San Diego, CA) for treating concussions has been initiated. The compound being tested is a synthetic form of the end
- FDA Extends Expiration Dating for Diazepam Nasal Sprayhttps://practicalneurology.com/news/fda-extends-expiration-dating-for-diazepam-nasal-spray/2469404/The Food and Drug Administration (FDA) has granted extended expiration dating for diazepam nasal spray (Valtoco; Neurelis, Inc., San Diego, CA). Diazepam was approved by the FDA on January 10, 2020, for the acute treatment of intermittent stereotypic episodes of frequent seizure activity th
- Opicapone Decreases Off Time in Parkinson Diseasehttps://practicalneurology.com/news/opicapone-decreases-off-time-in-parkinson-disease/2469380/Post hoc analyses presented at the Movement Disorder Society's Virtual Congress 2020 September 12-16 showed once-daily opicapone (Ongentys; Neurocrine Biosciences, San Diego, CA) decreased off time’ and increased on time without troublesome dyskinesia in Parkinson disease (PD). Opicapon
- FDA Accepts Supplemental New Drug Application for Pimavanserin for Dementia-Related Psychosis Symptomshttps://practicalneurology.com/news/fda-accepts-supplemental-new-drug-application-for-pimavanserin-for-dementia-related-psychosis-symptoms/2469329/The Food and Drug Administration (FDA) has accepted for filing its supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The sNDA is